Rasio utang jangka cendhak marang ekuitas: Athira Pharma, Inc. (ATHA)

Historical price action reflects the financial standing of Athira Pharma, Inc. (ATHA), whose strategy is based on developing drugs for the regeneration of neural connections in Alzheimer's disease. Athira Pharma, Inc. (ATHA) utilizes unique cell growth stimulation methods to combat brain degradation. The current metric is 0.01. The stability of scientific research is maintained through the seamless operation of modern laboratory complexes and screening systems.

This ratio determines the company's dependence on liabilities maturing within one year relative to its equity, serving as an indicator of financial autonomy and protection against sudden defaults. By analyzing the short-term debt-to-equity chart, an investor will see the critical dependence of Athira Pharma, Inc. (ATHA) on liquidity, as the lack of profit makes any borrowing a fatal risk to the project's survival.